Core One Labs -- top oder flop? (Seite 16)
eröffnet am 10.07.20 10:01:29 von
neuester Beitrag 17.05.24 04:52:54 von
neuester Beitrag 17.05.24 04:52:54 von
Beiträge: 3.038
ID: 1.327.544
ID: 1.327.544
Aufrufe heute: 5
Gesamt: 330.047
Gesamt: 330.047
Aktive User: 0
ISIN: CA21872J3073 · WKN: A3CSSU · Symbol: LD6
0,1340
EUR
0,00 %
0,0000 EUR
Letzter Kurs 19.05.24 Lang & Schwarz
Neuigkeiten
12.12.23 · Inult Anzeige |
11.12.23 · Inult Anzeige |
10.12.23 · Inult Anzeige |
09.12.23 · Inult Anzeige |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0400 | +46,48 | |
| 2,3300 | +42,07 | |
| 1,1400 | +30,85 | |
| 2,7700 | +25,91 | |
| 2,2000 | +13,40 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3100 | -16,61 | |
| 0,9100 | -17,27 | |
| 3,0900 | -17,38 | |
| 4,2300 | -18,65 | |
| 5,0000 | -37,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sauft äh kauft schön liebe Schäfchen;
https://www.wallstreet-online.de/nachricht/17212155-ad-hoc-a…
An diesem WE wird Polli besonders Promoten, da in Kanada die Börsen am Montag geschlossen haben.
https://www.wallstreet-online.de/nachricht/17212155-ad-hoc-a…
An diesem WE wird Polli besonders Promoten, da in Kanada die Börsen am Montag geschlossen haben.
Core One Labs Applauds Groundbreaking Research on Psilocybin as a Potential Anorexia Treatment
Vancouver, British Columbia, Canada – August 3, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) commends the groundbreaking research published in the journal Nature Medicine[1], which explores the potential of psilocybin, the main psychoactive ingredient in magic mushrooms, as a treatment for anorexia nervosa.
The study, conducted with 10 female patients suffering from anorexia, has yielded promising results, with participants reporting positive experiences and an impressive four patients achieving remission of their symptoms after receiving a single dose of psilocybin under the guidance of trained therapists. This pioneering research provides the first evidence for the safety and potential effectiveness of psilocybin as an anorexia treatment.
Anorexia nervosa is a severe mental illness affecting a significant number of individuals, yet the disorder has no approved medications available. With the highest mortality rate of any psychiatric disorder and a high likelihood of relapse, the urgent need for effective treatments is evident. These initial findings from the psilocybin trial offer hope for a potential new treatment option that could transform the lives of those suffering from this debilitating condition.
Dr. Walter Kaye, senior author of the study results and professor of psychiatry at the University of California, San Diego, noted that the study's results suggest that psilocybin administration may help reverse altered serotonin function in anorexia nervosa, leading to a new perspective on symptoms and behaviors in patients.
Core One Labs recognizes the significance of this research in advancing the understanding of mental health treatments and is encouraged by the many and continued groundbreaking studies that offer hope and potential relief for individuals battling mental health disorders. The Company looks forward to the further development of psilocybin as a potential treatment option for anorexia, and many other mental health and neurological disorders with the ultimate goal of improving the lives of those affected by this challenging condition.
The Company announces that it has entered into a debt settlement agreement (the “Agreement”) with an arms-length creditor of the Company. Pursuant to the Agreement, the Company has agreed to issue an aggregate amount of 62,520 common shares (“Common Shares”) in the capital of the Company at a deemed price of $0.52 per Common Share to settle an aggregate amount of $32,510.63 of outstanding debt (the “Shares for Debt Transaction”). The Company anticipates issuing the Common Shares in connection with the Shares for Debt Transaction on or about August 10, 2023. All securities issued pursuant to the Shares for Debt Transaction will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable securities legislation.
The Company also announces that it has granted a total of 100,000 Restricted Share Units (the “RSUs”) to a director of the Company under its 10% rolling Restricted Share Unit Plan. The RSUs will vest in four (4) months. All the RSUs (and any common shares issuable upon redemption) will be subject to a hold period of four (4) months and one (1) day from the date of issuance, in accordance with applicable securities legislation.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-888-452-6731
Vancouver, British Columbia, Canada – August 3, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) commends the groundbreaking research published in the journal Nature Medicine[1], which explores the potential of psilocybin, the main psychoactive ingredient in magic mushrooms, as a treatment for anorexia nervosa.
The study, conducted with 10 female patients suffering from anorexia, has yielded promising results, with participants reporting positive experiences and an impressive four patients achieving remission of their symptoms after receiving a single dose of psilocybin under the guidance of trained therapists. This pioneering research provides the first evidence for the safety and potential effectiveness of psilocybin as an anorexia treatment.
Anorexia nervosa is a severe mental illness affecting a significant number of individuals, yet the disorder has no approved medications available. With the highest mortality rate of any psychiatric disorder and a high likelihood of relapse, the urgent need for effective treatments is evident. These initial findings from the psilocybin trial offer hope for a potential new treatment option that could transform the lives of those suffering from this debilitating condition.
Dr. Walter Kaye, senior author of the study results and professor of psychiatry at the University of California, San Diego, noted that the study's results suggest that psilocybin administration may help reverse altered serotonin function in anorexia nervosa, leading to a new perspective on symptoms and behaviors in patients.
Core One Labs recognizes the significance of this research in advancing the understanding of mental health treatments and is encouraged by the many and continued groundbreaking studies that offer hope and potential relief for individuals battling mental health disorders. The Company looks forward to the further development of psilocybin as a potential treatment option for anorexia, and many other mental health and neurological disorders with the ultimate goal of improving the lives of those affected by this challenging condition.
The Company announces that it has entered into a debt settlement agreement (the “Agreement”) with an arms-length creditor of the Company. Pursuant to the Agreement, the Company has agreed to issue an aggregate amount of 62,520 common shares (“Common Shares”) in the capital of the Company at a deemed price of $0.52 per Common Share to settle an aggregate amount of $32,510.63 of outstanding debt (the “Shares for Debt Transaction”). The Company anticipates issuing the Common Shares in connection with the Shares for Debt Transaction on or about August 10, 2023. All securities issued pursuant to the Shares for Debt Transaction will be subject to a hold period of four months and one day from the date of issuance, in accordance with applicable securities legislation.
The Company also announces that it has granted a total of 100,000 Restricted Share Units (the “RSUs”) to a director of the Company under its 10% rolling Restricted Share Unit Plan. The RSUs will vest in four (4) months. All the RSUs (and any common shares issuable upon redemption) will be subject to a hold period of four (4) months and one (1) day from the date of issuance, in accordance with applicable securities legislation.
Core One Labs Inc.
Joel Shacker
Chief Executive Officer
FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-888-452-6731
Das wird ein Fest am Montag.
Antwort auf Beitrag Nr.: 74.259.735 von straßenköter am 04.08.23 10:38:07
😂😂😂 was ein Rat... -ihr selbsternannten Besserwissenden geht mir hier so auf den Sack 🙋♂️
Ich investiere nicht, ich trade, und da lassen sich einige, längst nicht alle beworbenen Werte ideal nutzen
Zitat von straßenköter: Dann gucke dir doch endlich mal an, was Polli die letzten Jahre beworben hat und was da jeweils raus gekommen ist
😂😂😂 was ein Rat... -ihr selbsternannten Besserwissenden geht mir hier so auf den Sack 🙋♂️
Ich investiere nicht, ich trade, und da lassen sich einige, längst nicht alle beworbenen Werte ideal nutzen
Bei mir ein großes Minus, aber ich bin halt zu gutgläubig.
Trading Spotlight
Antwort auf Beitrag Nr.: 74.259.663 von 19mini99 am 04.08.23 10:29:59Dann gucke dir doch endlich mal an, was Polli die letzten Jahre beworben hat und was da jeweils raus gekommen ist
Antwort auf Beitrag Nr.: 74.259.399 von Eezay am 04.08.23 10:03:58
Im Gegensatz zu dir und anderen hier, wie z.B auch Barönchen und Köter, informiere ich konstruktiv um jedem die Möglichkeit zu geben sich sein eigenes Bild zu machen. Ich rede weder zu gut, noch zu schlecht
Zitat von Eezay:Zitat von 19mini99: https://inult.com/sondermeldung-08042023
Hochgradig heiße Luft
Im Gegensatz zu dir und anderen hier, wie z.B auch Barönchen und Köter, informiere ich konstruktiv um jedem die Möglichkeit zu geben sich sein eigenes Bild zu machen. Ich rede weder zu gut, noch zu schlecht
Antwort auf Beitrag Nr.: 74.258.454 von 19mini99 am 04.08.23 08:23:17
Hochgradig heiße Luft
Zitat von 19mini99: https://inult.com/sondermeldung-08042023
Hochgradig heiße Luft
https://www.marketscreener.com/quote/stock/CORE-ONE-LABS-INC…
Hier auch gleich der Text:
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023
Today at 02:32 pm
Core One Labs Inc. reported earnings results for the fifteen months ended March 31, 2023. For the fifteen months, the company reported sales was CAD 0.573177 million. Net loss was CAD 19.98 million.
Basic loss per share from continuing operations was CAD 0.61. Diluted loss per share from continuing operations was CAD 0.61. Basic loss per share was CAD 0.61.
Diluted loss per share was CAD 0.61.
Hier auch gleich der Text:
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023
Today at 02:32 pm
Core One Labs Inc. reported earnings results for the fifteen months ended March 31, 2023. For the fifteen months, the company reported sales was CAD 0.573177 million. Net loss was CAD 19.98 million.
Basic loss per share from continuing operations was CAD 0.61. Diluted loss per share from continuing operations was CAD 0.61. Basic loss per share was CAD 0.61.
Diluted loss per share was CAD 0.61.
Durchsuchen
Core One Labs -- top oder flop?
